Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Core Viewpoint - Inhibikase Therapeutics, Inc. has entered into a securities purchase agreement to raise approximately $4.0 million through a registered direct offering and concurrent private placement, aimed at advancing its clinical-stage therapeutics for Parkinson's disease and related disorders [1][3]. Group 1: Securities Offering Details - The company will sell 1,672,452 shares of common stock at a price of $1.68 per share, along with Series A and Series B warrants, each with an exercise price of $1.68 [1][2]. - The Series A warrants will expire one year from stockholder approval, while the Series B warrants will expire five years from stockholder approval [1][2]. - The gross proceeds from the offering are estimated to be approximately $4.0 million before deducting fees and expenses [3]. Group 2: Warrant Inducement Agreement - Inhibikase has entered into a warrant inducement agreement with an investor to exercise outstanding warrants for 708,500 shares at an amended exercise price of $1.68 [2]. - The company will also issue Series C and Series D warrants, each with an exercise price of $1.68, which will have similar expiration terms as the Series A and B warrants [2]. Group 3: Company Overview - Inhibikase Therapeutics is focused on developing therapeutics for Parkinson's disease and related disorders, with its lead program targeting the treatment of neurodegeneration [6][7]. - The company is headquartered in Atlanta, Georgia, and has a multi-therapeutic pipeline that includes various drug delivery technologies and follow-on compounds [6][7].